The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
about
The multidrug transporter ABCG2: still more questions than answersBlood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in strokeRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceTargeting transporters: promoting blood-brain barrier repair in response to oxidative stress injuryEarly sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyBCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenibStrategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data.Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Choroid plexus transport: gene deletion studies.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team upBrain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearanceTargeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.Contribution of tumoral and host solute carriers to clinical drug response.Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout miceImpact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)Brain distribution and bioavailability of elacridar after different routes of administration in the mouse.Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor modelActive efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastasesNABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer TreatmentsSorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance proteinPhysiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approachDelivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.Role of tyrosine kinase inhibitors in the management of high-grade gliomas.Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
P2860
Q26747187-AD3D3498-93D3-4835-B581-CEAC00BB586AQ26864317-8B541348-03A6-4267-A2EF-4ABF1C15B8E2Q26865927-7692866E-D37F-4A72-8B41-F96949845FC5Q28088708-8BB46B27-E933-4011-8FE3-5D685FC1D906Q28482219-6BA68493-793A-4AD7-AD8E-EC2137DB20FCQ28538126-3016C173-5E5E-4B3E-AC5A-2986DA76908DQ30366921-5D506505-41B4-4DF5-A2D2-383FA7FC8EA1Q30664269-137685F0-2B11-4DB4-91EA-0B67E1B9B6EDQ33404027-0F207CC6-D6C4-47AC-928E-7FDAE75AB667Q33414998-4EC367B7-D907-420B-AEB3-23D5AB0E4BE6Q34871636-DE9292D6-CCE1-45C1-A8F2-DDC78457362BQ35171274-16A8EF4E-4478-4F39-AF77-DDB3A7F566BBQ35596169-F7AB7893-C8BA-4755-B10B-289F8C1E4E50Q35708124-F5041E6F-7898-4067-B6B6-3AC810EEFBD6Q35720625-D3C10B87-B22B-4C55-A40D-61AB86E01156Q35743315-2DFB40D0-1C9C-4F99-B858-177DEFFC9AFDQ35799917-37813634-55DB-475D-8E42-0C44B2BBD417Q35810745-705257FD-1B26-4380-A0AA-06C4E40B828EQ35855634-66B36649-4526-4179-8A7E-8E2732E9474BQ35913169-B3D2F80B-D6EA-4338-840A-F3A5CACCA73BQ35946876-4AE2FBCA-A861-42D8-BA87-80DA4E281ED6Q35996449-5B1E5FF7-32C3-443C-A15F-DF2B62D2BC5EQ36057973-8BED3CEC-8D1D-4CCC-ABD4-9EE55D2A594CQ36105340-C5886EF7-0ABC-45DF-8148-B2120CA595B4Q36186193-1BC657C3-F476-4822-A8B5-A78A910C2857Q36312901-52A12136-9BD2-49E5-8D67-6A2C94736C2DQ36497633-C07F5809-E8F5-44E0-AE33-04DA3632E755Q36613936-803CCF59-1163-45B5-95D5-7F6A4A93FD13Q36642420-91F45056-1E3C-493F-8E76-9D548678EABDQ36713494-FA91588B-FE61-45E2-ACDF-58D18661D2EFQ36717122-758799C0-83E1-4F94-B82F-33C94292D9A2Q36764312-B0049E82-323F-43B2-8914-311C3747AE30Q36852518-80F304E8-1C6D-44F5-A27C-9F61A8271852Q36949859-A6931F40-C585-4AF5-8F9E-0BA5C33DD5A5Q37207750-C1EF6D67-1D08-4915-B35C-EE941D6F4E9CQ37308322-A8459708-CD19-41B2-8010-C3259D9FD82EQ37331814-3C2171BB-260B-4D5A-A576-166D2577A5C2Q37663394-B0C618E2-3FB0-4EA9-B180-EB73D3186960Q37952242-82AF16C7-14A5-44D3-9ABE-4CF0240CAAF3Q37958162-B1E4C248-D29B-4810-9029-EE188D335CA4
P2860
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The role of the breast cancer ...... ion of sorafenib to the brain.
@ast
The role of the breast cancer ...... ion of sorafenib to the brain.
@en
The role of the breast cancer resistance protein
@nl
type
label
The role of the breast cancer ...... ion of sorafenib to the brain.
@ast
The role of the breast cancer ...... ion of sorafenib to the brain.
@en
The role of the breast cancer resistance protein
@nl
prefLabel
The role of the breast cancer ...... ion of sorafenib to the brain.
@ast
The role of the breast cancer ...... ion of sorafenib to the brain.
@en
The role of the breast cancer resistance protein
@nl
P2093
P2860
P356
P1476
The role of the breast cancer ...... ion of sorafenib to the brain.
@en
P2093
John R Ohlfest
Ramola Sane
Sagar Agarwal
William F Elmquist
P2860
P304
P356
10.1124/JPET.110.175034
P407
P577
2010-10-15T00:00:00Z